• Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
Economy

Hawley blasts FDA approval of new abortion drug, cites safety and trust concerns

by October 3, 2025
by October 3, 2025

Sen. Josh Hawley, R-Mo., accused the Food and Drug Administration (FDA) of endangering women’s health, saying the agency approved another chemical abortion drug without the thorough safety review it had promised.

Hawley argued the move shows both regulatory failure and the influence of a company that refuses to define ‘woman’ in its materials.

‘This is shocking. FDA has just approved ANOTHER chemical abortion drug, when the evidence shows chemical abortion drugs are dangerous and even deadly for the mother. And of course 100% lethal to the child,’ he wrote on X on Thursday afternoon.

Hawley added, ‘FDA had promised to do a top-to-bottom safety review of the chemical abortion drug, but instead they’ve just greenlighted new versions of it for distribution. I have lost confidence in the leadership at FDA.’

Evita Solutions describes its mission as to ‘normalize abortion’ and make it ‘accessible to all.’ On its website, the company says it ‘believes that all people should have access to safe, affordable, high-quality, effective, and compassionate abortion care, regardless of their race, sex, gender, age, sexuality, income, or where they live.’

It adds, ‘We know that you can make the best choice for your body.’

According to the FDA, Evita received approval in a Sept. 30 letter obtained by Reuters.

In an interview with Fox News Digital, Hawley said the FDA’s decision was even more troubling given that its promised safety review has barely begun.

‘I just, I can’t figure out what’s happening at the FDA. I’m totally baffled by it,’ Hawley said.

Fox News Digital has reached out to the FDA and Evita Solutions for comment on the matter.

In another post, Hawley blasted the FDA for partnering with a company that ‘doesn’t even believe there is such a thing as a ‘woman.’’

Evita Solutions now joins GenBioPro in producing the generic version of Mifepristone, the abortion pill originally made by Danco Laboratories. Mifepristone blocks progesterone, a hormone needed to sustain pregnancy, and is followed by misoprostol to complete the process.

The approval comes as abortion drugs face mounting opposition from conservative lawmakers, religious organizations, and pro-life groups.

Religious groups like Inspire Investing and Alliance Defending Freedom have campaigned against the drug, while the Restoration of America Foundation (ROAF) has pressed lawmakers for accountability.

Last month, ROAF called on the Senate Finance Committee to hold Health and Human Services Secretary Robert F. Kennedy Jr. accountable at a hearing, demanding answers about the removal of safety protocols for the abortion pill Mifepristone.

In a letter obtained by Fox News Digital, ROAF warned that the rollback leaves women more vulnerable and shifts costs to taxpayers. The group said the Biden-era changes endanger women by allowing abortion pills to be prescribed via telehealth and sent through the mail.

Hawley said the FDA should restore the safeguards put in place under the Trump administration.

‘What needs to happen is the FDA needs to get in line with the president’s policy and put back into place the safety regulations President Trump had. Ditch the Biden approach and go back to President Trump’s approach,’ Hawley said.

Under the Biden administration, the FDA for the first time allowed telehealth prescribing and mail-order delivery of abortion pills. Previously, the agency required Mifepristone to be dispensed in person to screen for complications such as ectopic pregnancy.

Fox News Digital’s Jasmine Baehr and Reuters contributed to this report.

This post appeared first on FOX NEWS

0 comment
0
FacebookTwitterPinterestEmail

previous post
Wiliot and Walmart Partner to Transform Retail with Ambient IoT and AI
next post
Reagan-appointed judge, once rebuked by Supreme Court, continues to lambaste Trump

Related Posts

DAVID MARCUS: Ben Sasse is dying, but his...

December 28, 2025

Zelenskyy says fresh Russian attack on Ukraine shows...

December 28, 2025

Trump’s peace through strength in 2025: where wars...

December 28, 2025

Most shocking examples of Chinese espionage uncovered by...

December 28, 2025

Zelenskyy says Ukraine, ahead of Trump meeting, is...

December 28, 2025

2025 shockers: The biggest moments that rocked the...

December 28, 2025

Iranian president says his country is at ‘total...

December 28, 2025

Israel FM accuses Palestinian Authority of aiding terror...

December 27, 2025

2026 deadlines loom as Congress leaves DC with...

December 27, 2025

Trump casts Maduro’s ouster as ‘smart’ move as...

December 27, 2025

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

Recent Posts

  • Looking back at 2025: the $3.2 billion Fintech IPO comeback nobody predicted

    December 28, 2025
  • What US GDP report means for Fed’s rate decision in January

    December 28, 2025
  • Why Southwest emerged as the top US airline stock in 2025?

    December 28, 2025
  • Commerzbank anticipates wheat price recovery by end of 2026 on supply constraints

    December 28, 2025
  • Nvidia stock: how Groq deal removes the last remaining bear case

    December 28, 2025
  • From Walgreens to EA: 2025 marked a banner year for take-private deals

    December 28, 2025

Editors’ Picks

  • 1

    Pop Mart reports 188% profit surge, plans aggressive global expansion

    March 26, 2025
  • 2

    Meta executives eligible for 200% salary bonus under new pay structure

    February 21, 2025
  • 3

    New FBI leader Kash Patel tapped to run ATF as acting director

    February 23, 2025
  • 4

    Walmart earnings preview: What to expect before Thursday’s opening bell

    February 20, 2025
  • 5

    Anthropic’s newly released Claude 3.7 Sonnet can ‘think’ as long as the user wants before giving an answer

    February 25, 2025
  • 6

    Cramer reveals a sub-sector of technology that can withstand Trump tariffs

    March 1, 2025
  • 7

    Nvidia’s investment in SoundHound wasn’t all that significant after all

    March 1, 2025

Categories

  • Economy (3,628)
  • Editor's Pick (374)
  • Investing (318)
  • Stock (2,450)
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Read alsox

Experts gauge success of ‘bunker buster’ bombs...

June 25, 2025

Uber’s Gender Features Put Customers in the...

August 13, 2025

What Hamburger Helper Knows and GDP Misses

October 14, 2025